IFN-γ (+874) and not TNF-α (-308) is associated with HBV-HCC risk in India - PubMed (original) (raw)

. 2014 Jan;385(1-2):297-307.

doi: 10.1007/s11010-013-1838-9. Epub 2013 Oct 8.

Affiliations

IFN-γ (+874) and not TNF-α (-308) is associated with HBV-HCC risk in India

Roli Saxena et al. Mol Cell Biochem. 2014 Jan.

Abstract

Tumor necrosis factor (TNF)-α and interferon (IFN)-γ, the pro-inflammatory Th1 cytokines are the indispensable coordinators of the inflammatory responses involved in hepatitis B virus (HBV) pathogenesis. This study attempted to evaluate any possible association among TNF-α (-308G>A) and IFN-γ (+874T/A) genotypes, the spontaneous blood and mRNA levels and expression of their major signal transducers, namely STAT1 and NF-кB with hepatitis B virus-induced hepatocellular carcinoma (HCC) susceptibility in India. For this, 398 subjects (146 controls, 68 inactive-HBV-carriers, 64 chronic-active HBV patients, 61 HBV-cirrhotics, and 59 HBV-HCC subjects) were enrolled. Polymerase chain reaction-restriction fragment length polymorphism, allele-specific PCR, enzyme-linked immunosorbent assay, reverse transcriptase-PCR, and Western blot analysis were done for assessing polymorphism, blood levels, mRNA expression, and protein expression of signal transducers, respectively, of TNF-α and IFN-γ. The study revealed no significant association of TNF-α (-308) GA genotype, while a significant negative association of IFN-γ (+874) TA and AA genotypes, in HBV-HCC risk. Moreover, blood levels of TNF-α were significantly elevated as disease progresses to HCC, while IFN-γ levels were raised in HCC patients only. Besides, IFN-γ mRNA levels were significantly elevated in cirrhotics, with no change observed in TNF-α transcript levels. Moreover, NF-кB expression also consistently increased during HCC progression. These observations suggest a vital negative association of IFN-γ (+874) with HBV-HCC risk, with no significant association evident in TNF-α (-308). However, the TNF-α and IFN-γ levels markedly increased in HCC development.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Rheumatology (Oxford). 2003 Feb;42(2):308-13 - PubMed
    1. Clin Vaccine Immunol. 2009 Jun;16(6):811-5 - PubMed
    1. World J Gastroenterol. 2006 Feb 28;12(8):1175-81 - PubMed
    1. Cytokine. 2006 Apr;34(1-2):24-31 - PubMed
    1. Methods Enzymol. 1996;272:199-210 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources